Company Overview
InspireMD, Inc. is a medical device company dedicated to the development and commercialization of innovative products specifically designed for the treatment of carotid artery disease and other vascular conditions. The company operates within the broader Healthcare sector, focusing on the Medical Devices industry, which implies a specialized environment requiring rigorous regulatory compliance and high technical expertise in biomedical engineering. As of the latest data, InspireMD, Inc. maintains a market capitalization of $67.37M and employs a workforce of 127 individuals across its operations. While the company reports an annual revenue of $8.98M over the trailing twelve months, these figures indicate a small-cap enterprise with a relatively modest scale compared to established industry leaders. The combination of a market cap under $100 million and annual revenue below $10 million suggests the company is in a growth phase where it is still establishing its foothold in the international market, which includes the United States, Germany, Italy, Russia, Poland, and other international regions.
Financial Health
Over the trailing twelve months, the company generated revenue of $8.98M, yet reported a net income of $-48,786,000 and an EBITDA of $-49,138,000. The substantial gap between the positive revenue of $8.98M and the significant net loss reveals a cost structure characterized by heavy upfront expenditures, likely related to research and development or commercialization efforts that exceed current sales proceeds. The free cash flow stands at $-18,728,750, indicating that the company is currently burning cash to fund its operations and product development initiatives rather than generating surplus liquidity. This negative cash flow profile necessitates careful management of capital reserves to maintain financial flexibility until the business achieves operational profitability. The gross margin is reported at 29.5%, which suggests that the company retains nearly 30% of revenue after direct costs of goods sold, a reasonable figure for medical device manufacturers. However, the operating margin is deeply negative at -383.7%, and the profit margin is 0.0%, reflecting the immense overhead costs associated with being a loss-making entity. The balance sheet shows a cash position of $54.21M against total debt of $3.29M, creating a significant liquidity buffer, though the debt-to-equity ratio of 5.96 indicates a highly leveraged capital structure relative to shareholders' equity. Despite the high leverage, the current ratio of 5.74 demonstrates strong short-term liquidity, meaning the company holds more than five times the current assets necessary to cover its current liabilities. Finally, the return on equity is -106.9% and the return on assets is -53.4%, metrics that reveal that management has not yet generated positive returns on the capital invested by shareholders or utilized in assets.
Valuation Assessment
The valuation metrics present a complex picture given the company's financial status, with a trailing P/E ratio listed as N/A due to the lack of net income. The forward P/E ratio is -2.62, a negative figure that implies the market is pricing in expected future earnings growth to eventually overcome current losses. The price-to-book ratio is 1.25, indicating that the stock trades at a 25% premium over its book value, which may reflect investor confidence in the underlying technology or future revenue potential despite current losses. Additionally, the price-to-sales ratio is 7.50, and the EV/EBITDA is -0.48, suggesting that the market values the company based on its revenue generation capabilities rather than current profitability. The stock has exhibited volatility over the past year, trading between a 52-week high of $2.93 and a 52-week low of $1.51. Based on the available price metrics, the current trading price sits below the 52-week high of $2.93, reflecting the typical behavior of a small-cap biotech or device firm subject to market sentiment shifts. The beta value is 0.93, which indicates that the stock's price volatility is roughly in line with the broader market, moving neither significantly more nor less volatile than the S&P 500.
Growth & Income
InspireMD, Inc. demonstrates robust top-line expansion with revenue growth of 61.6% year-over-year, while earnings growth is N/A due to the company's continued negative net income. The fact that revenue is growing while earnings remain negative implies that the company is investing heavily in growth initiatives that have not yet translated into bottom-line profitability. As a non-dividend payer, the company does not distribute a dividend yield or has a payout ratio of 0.0%, meaning all available cash is reinvested back into the business to support product development and market expansion. This growth-over-income profile is typical for early-stage medical device companies that prioritize scaling their product portfolio over returning capital to shareholders. The overall growth and income profile is defined by aggressive revenue expansion funded by cash reserves, with no reliance on dividend income for investors seeking yield.